Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Clodronate Disodium Tablets.

Functions and indications:
1. Hypercalcemia complicated by malignant tumors. 2. Bone pain caused by osteolytic cancer metastasis. 3. It can avoid or delay osteolytic bone metastasis of malignant tumors. 4. Various types of osteoporosis.
Usage and dosage:
This product has a variety of dosage forms and specifications. The same medicine produced by different manufacturers may have inconsistent instructions. Please read the drug instructions carefully before taking the medicine and follow the doctor’s instructions. Clodronate disodium tablets/clodronate disodium injection: 1. Paget’s disease: 300mg/day, intravenous drip for more than 3 hours, a total of 5 days, and then change to oral administration. 2. Hypercalcemia: 300mg/day, intravenous drip for 3-5 days or 1.5g intravenous drip once, and change to oral administration after blood calcium returns to normal. Clodronate disodium capsules: Oral. 1. Patients with malignant tumors: 2.4g per day, which can be taken in 2-3 times. For patients with normal serum calcium levels, it can be reduced to 1.6g per day. If accompanied by hypercalcemia, it can be increased to 3.2g per day. It must be taken on an empty stomach, preferably 1 hour before meals. 2. All types of osteoporosis in the early stage or without bone pain: 0.4g per day, 3 months as a course of treatment, and the course can be repeated if necessary. All types of osteoporosis with severe or bone pain, 1.6g per day, taken in two times, or follow the doctor’s advice. Disodium clodronate for injection: 1. Intravenous infusion is only suitable for short-term treatment. 2. Clodronate is mainly cleared by the kidneys, so adequate water intake must be maintained during clodronate treatment. Adequate water intake must be ensured, and renal function and serum calcium concentration should be monitored before and during treatment. 3. After clodronate infusion, different patients have significant differences in the length of time they can maintain clinically acceptable serum calcium concentrations. If necessary, repeated infusions can be used to control serum calcium levels or oral clodronate treatment can be selected. 4. Adult patients with normal renal function: When clodronate is intravenously infused, the daily dose is 300 mg, diluted with 500 ml of saline (sodium chloride at 9 mg/ml) or 500 ml of 5% glucose (50 mg/ml) solution. The infusion time of the prepared solution should be at least 2 hours, and the infusion should be continued for several days until normal blood calcium levels are reached, which is usually achieved within 5 days. Under normal circumstances, this continuous treatment should not exceed 7 days. 5. Patients with renal failure: See the instructions for details.
Adverse reactions:
1. The most commonly reported adverse reactions are gastrointestinal reactions, such as nausea, vomiting and diarrhea. They occur in about 10% of patients. However, these reactions are usually mild and often occur at high doses. In a randomized, placebo-controlled clinical trial for the prevention of bone metastasis in patients with surgically treatable primary breast cancer, 1,079 patients were evaluated for safety. Among the adverse events that occurred in the clodronate group, only non-severe diarrhea was significantly more common than in the placebo control group. 2. Metabolic and nutritional abnormalities: (1) Common: Asymptomatic hypocalcemia. (2) Rare: Symptomatic hypocalcemia. (3) Elevated serum parathyroid hormone levels are often associated with decreased serum calcium levels. Changes in serum alkaline phosphatase concentrations have been observed, and serum alkaline phosphatase levels are elevated in patients with liver and bone metastases. 3. Respiratory, thoracic and mediastinal abnormalities: Very rare: Respiratory impairment in patients with aspirin-allergic asthma. Allergic reactions manifest as respiratory symptoms. 4. Gastrointestinal abnormalities: Common: Nausea, vomiting and diarrhea, usually mild. 5. Hepatobiliary abnormalities: (1) Common: Elevated transaminases, but usually within the normal range. (2) Rare: Elevated transaminases more than twice the normal range, not accompanied by liver damage. 6. Skin and subcutaneous tissue abnormalities: Rare: The same manifestations as allergic skin reactions. 7. Kidney and urinary system abnormalities: Rare: Renal impairment (elevated serum creatinine and proteinuria); severe renal impairment, especially after rapid intravenous infusion of high-dose clodronate (for dosage, see “Dosage and Administration”).
1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe renal damage and osteomalacia are prohibited from using this product.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.